Abstract: Provided is a medicinal composition to be topically administered for tooth regeneration therapy, said composition comprising an RNA molecule targeting USAG-1 or a nucleic acid molecule capable of yielding the RNA molecule and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a cell support including a base material containing a biocompatible substance or a base material having a surface to which the biocompatible substance is imparted, and gelatin particles held by the biocompatible substance of the base material. The cell support can be produced by a method of causing the base material containing a biocompatible substance to hold the gelatin particles. By seeding cells on the cell support and culturing the cells, a cell structure in which a reagent or a drug has been uniformly taken into more cells can be obtained.

Abstract: The present invention relates to a cell-supporting body, including: a base material including a biocompatible substance; and a gelatin particle retained on the base material. The cell-supporting body can be manufactured by a method of retaining a gelatin particle on a base material including a biocompatible substance. By seeding a cell on the cell-supporting body and culturing the cell, a cell structure in which a reagent or an agent is uniformly incorporated into more cells can be obtained.

Abstract: The present invention provides a prophylactic or therapeutic agent for the leakage of pancreatic juice and/or pancreatic fistula after abdominal surgery, containing a lipase inhibitor as an active ingredient, and a method for preventing or treating leakage of pancreatic juice and/or pancreatic fistula after abdominal surgery, including administering an effective amount of a lipase inhibitor to a mammal in need of the administration thereof.

Abstract: A cell freezing composition according to the present invention includes a medium, an antifreezing agent, and dissolved hydrogen.

Abstract: Disclosed herein are gelatin particles including gelatin, wherein when a major-axis length of dried gelatin particles is defined as a and a major-axis length of gelatin particles after swelling treatment obtained by immersing the dried gelatin particles in water at 40° C. under an atmospheric pressure for 60 minutes is defined as b, swelling degree represented by b/a is 1.0 or more but 10.0 or less, and wherein the gelatin particles after swelling treatment have a particle diameter of 1.0 nm or more but 5.0 ?m or less. The gelatin particles are easily taken up by cells themselves.

Abstract: The present invention provides a highly safe non-lamellar liquid crystal-forming composition. The present invention relates to a non-lamellar liquid crystal-forming composition comprising a phospholipid and an amphipathic compound represented by the following general formula (I), wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes the integer 1 or 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group having one or more hydroxyl groups, and wherein the composition has an increased biocompatibility by the phospholipid.

Abstract: An object of the present invention is to provide a method for assessing a differentiation state of cells, capable of assessing a differentiation state of a wide variety of cells, and gelatin nanoparticles and a gelatin nanoparticle set that can be used in the method. The purpose is achieved by a method for assessing a differentiation state of cells, the method including a step of observing expression of an mRNA encoding a peroxisome proliferator-activated receptor ? coactivator-1? (PGC-1?) or the peroxisome proliferator-activated receptor ? coactivator-1? (PGC-1?) in cells.

Abstract: The purpose of the present invention is to provide: a method which is for assessing the differentiation state of cells and by which the differentiation state of a wide variety of cells can be assessed; and gelatin nanoparticles which can be used in said method. The purpose is achieved by a method for assessing the differentiation state of cells, the method comprising a step for observing the expression of pyruvate dehydrogenase kinase 1 (PDK1) or mRNA (Pdk1) encoding pyruvate dehydrogenase kinase 1 in cells. Said method can be carried out by using gelatin nanoparticles which are used for assessing the differentiation state of cells and carry a probe capable of detecting Pdk1 or PDK1.

Abstract: A statin-encapsulated nanoparticle contains a bioabsorbable polymer and statin encapsulated in the nanoparticle. Suitable bioabsorbable polymers include a polylactic acid (PLA) polymer or a polylactic acid-glycolic acid (PLGA) copolymer. The statin-encapsulated nanoparticle can be used to enhance the function of a stem cell. The stem cell can be a stem cell for treating an inflammatory disease.

Abstract: A statin-encapsulated nanoparticle contains a bioabsorbable polymer and statin encapsulated in the nanoparticle. Suitable bioabsorbable polymers include a polylactic acid (PLA) polymer or a polylactic acid-glycolic acid (PLGA) copolymer. The statin-encapsulated nanoparticle can be used to enhance the function of a stem cell. The stem cell can be a stem cell for treating an inflammatory disease.

Abstract: The present invention addresses the problem of providing: a hydrogel particle which can be taken into a cell by the action of the cell and can control the release of a magnetic particle enclosed therein into the cell so as to retain the magnetic particle in the cell for a long period; a method for producing the hydrogel particle; a cell or a cell structure each enclosing the hydrogel particle therein; and a method for evaluating the activity of a cell using the hydrogel particle. The present invention solves the problem by a hydrogel particle including: a domain which is composed of a first hydrogel; a matrix which encloses the domain and is composed of a second hydrogel having a different crosslinking degree or composition from that of the first hydrogel; and a magnetic particle which is supported by at least the first hydrogel.

Abstract: Provided is an agent for preserving a biological component, comprising a hydrogel, the hydrogel comprising a crosslinked product formed from a compound having a plurality of hydroxyl groups and a modified hyaluronic acid having substituents capable of reacting with the hydroxyl groups to form a crosslinked structure.

Abstract: The purpose of the present invention is to provide composite particles for imaging that have high biodegradability after imaging. To achieve the above purpose, the composite particles for imaging according to the present invention are configured such that the ratio (long-term residual amount/short-term residual amount) of a long-term residual amount, which is the average value of the contrast rate after six days in a cell and the contrast rate after 11 days in a cell of the same type, and a short-term residual amount, which is the contrast rate after two days in a cell of the same type, is less than 99%.

Abstract: Disclosed herein are gelatin particles that have been crosslinked without using a crosslinking agent and are easily taken up by cells themselves, and a method for producing such gelatin particles. The gelatin particles are made of self-crosslinked gelatin and have a particle diameter of 0.010 ?m or more but 5.0 ?m or less. The gelatin particles can be produced by discharging droplets of a liquid containing melted gelatin into air in a heating tube or a drying chamber and drying the droplets to form the gelatin into particles under conditions where a difference between the temperature in the heating tube or the drying chamber and the temperature of the liquid is 235° C. or less and further by crosslinking the gelatin forming the particles.

Abstract: A statin-encapsulated nanoparticle contains a bioabsorbable polymer and statin encapsulated in the nanoparticle. Suitable bioabsorbable polymers include a polylactic acid (PLA) polymer or a polylactic acid-glycolic acid (PLGA) copolymer. The statin-encapsulated nanoparticle can be used to enhance the function of a stem cell. The stem cell can be a stem cell for treating an inflammatory disease.

Abstract: A preparation containing a statin-encapsulated nanoparticle obtained by encapsulating statin in a nanoparticle containing a bioabsorbable polymer is disclosed. The nanoparticle has a number average particle diameter of less than 1000 nm. The preparation is used to enhance the function of a stem cell. A stem cell with an enhanced function is disclosed. The stem cell takes up and contains the statin-encapsulated nanoparticle.

Abstract: A cell culture base material for trait induction control of mesenchymal stem cells including an uneven pattern on a surface to which cells adhere and of which the width of the unevenness is greater than or equal to 50 nm and less than 1,000 nm. A trait control method of mesenchymal stem cells includes culturing mesenchymal stem cells on the cell culture base material for trait induction control of mesenchymal stem cells.

Abstract: Disclosed herein are gelatin particles that have been crosslinked without using a crosslinking agent and are easily taken up by cells themselves, and a method for producing such gelatin particles. The gelatin particles are made of self-crosslinked gelatin and have a particle diameter of 0.010 ?m or more but 5.0 ?m or less. The gelatin particles can be produced by discharging droplets of a liquid containing melted gelatin into air in a heating tube or a drying chamber and drying the droplets to form the gelatin into particles under conditions where a difference between the temperature in the heating tube or the drying chamber and the temperature of the liquid is 235° C. or less and further by crosslinking the gelatin forming the particles.

Abstract: Disclosed herein are gelatin particles including gelatin, wherein when a major-axis length of dried gelatin particles is defined as a and a major-axis length of gelatin particles after swelling treatment obtained by immersing the dried gelatin particles in water at 40° C. under an atmospheric pressure for 60 minutes is defined as b, swelling degree represented by b/a is 1.0 or more but 10.0 or less, and wherein the gelatin particles after swelling treatment have a particle diameter of 1.0 nm or more but 5.0 ?m or less. The gelatin particles are easily taken up by cells themselves.